16 results
8-K
EX-99.1
OVID
Ovid Therapeutics Inc
2 Oct 23
Dawn of the neurotherapeutics era Dr. Jeremy Levin CEO & Chairman
12:15pm
PLATFORM & OV888* SOTICLESTAT OV329 OV329 KCC2 PLATFORM & OV350
Environmental advances enabled the cancer revolution in our lifetime Unclear genesis … Prevented progression of spontaneous recurrent seizures Increased seizure threshold against environmental stimuli Improved survival Protection from seizure
8-K
EX-1.1
n53i9n9j
26 Aug 20
Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock
4:10pm
8-K
EX-1.2
75n3p32rmvg
7 Oct 19
Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
9:29pm
8-K
EX-1.1
7yebtisu2e9w7dl2i19
7 Oct 19
Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
9:29pm
8-K
EX-99.1
1rpbj 1xrbx
27 Jun 19
Regulation FD Disclosure
12:04pm
8-K
EX-1.1
tt1t41d vfl9udev9s
21 Feb 19
Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock
4:53pm
8-K
EX-1.2
889dcpo
21 Feb 19
Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock
4:53pm
S-3
EX-1.2
49t iblxw976a
1 Jun 18
Shelf registration
5:14pm
- Prev
- 1
- Next